18
Participants
Start Date
August 14, 2020
Primary Completion Date
March 23, 2022
Study Completion Date
October 11, 2022
AL101
AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
UZ Leuven, Leuven
Vall d'Hebron University Hospital, Barcelona
Institut Català d'Oncologia, Barcelona
Memorial Sloan Kettering Cancer Center (MSKCC), New York
Maryland Oncology Hematology, Columbia
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Charleston Oncology, Charleston
Rambam Medical Center, Haifa
Mayo Clinic, Jacksonville
H. Lee Moffitt Cancer Center, Tampa
Comprehensive Hematology Oncology, St. Petersburg
University of Louisville- James Brown Cancer Center, Louisville
University Health Cleveland Medical Center, Cleveland
University of Michigan, Ann Arbor
Rabin Medical Center, Petah Tikva
Mayo Clinic, Rochester
The University of Chicago, Chicago
Carle Clinic, Urbana
Central Cancer Care, Bolivar
University of Colorado, Aurora
Mayo Clinic, Phoenix
Banner MD Anderson Cancer Center, Gilbert
Hadassah Medical Center, Jerusalem
University of California at San Francisco, San Francisco
Kaplan Medical Center, Rehovot
Shaare Zedek Hospital, Jerusalem
Institut Jules Bordet, Brussels
The Christie Hospital, Manchester
University Hospital of Edinburgh, Edinburgh
Lead Sponsor
Ayala Pharmaceuticals, Inc,
INDUSTRY